Evidence map›Paper›PMID 26541937›Full record

Observational studyAlimentary pharmacology & therapeutics2016

Adjuvant use of antibiotics with corticosteroids in inflammatory bowel disease exacerbations requiring hospitalisation: a retrospective cohort study and meta-analysis.

V Gupta, R Rodrigues, D Nguyen, J Sauk, H Khalili, V Yajnik, A N Ananthakrishnan

Open access · bronzeAbstract readObservational Study
In one paragraph

Observational study in Alimentary pharmacology & therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Functional Plasmon-Activated Water IncreasesInternational journal of molecular sciences · 2022
    Article
  6. Gastrointestinal dysbiosis and Escherichia coli pathobionts in inflammatory bowel diseases.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2022
    Article
  7. The Periodontopathic Pathogen,Pathogens (Basel, Switzerland) · 2022
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. The Gut Microbiome as a Target for IBD Treatment: Are We There Yet?Current treatment options in gastroenterology · 2019
    Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

V GuptaDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
R RodriguesNorth Shore Community Health Center, Salem, MA, USA.
D NguyenDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
J SaukDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
H KhaliliDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
V YajnikDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
A N AnanthakrishnanDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Massachusetts General Hospital · USCommunity Health Center · USHarvard University · US

Funding

Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI ANDREW D LUSTER · 1991 to 2026
$35.3M
Oral Contraceptives in the Etiopathogenesis of Crohn's DiseaseK23DK099681 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI KHALILI, HAMED · 2013 to 2017
$946k
Genetic predictors of anti-TNF treatment response and infections in IBDK23DK097142 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI ANANTHAKRISHNAN, ASHWIN N · 2012 to 2016
$846k
NIDDK NIH HHS K23 DK097142NIDDK NIH HHS K23 DK099681NIDDK NIH HHS P30 DK043351
6 · The paper itself

Abstract

backgroundPatients hospitalised with an exacerbation of inflammatory bowel disease (IBD) often receive antibiotics in addition to intravenous steroids. However, their efficacy in this setting is unclear.

aimTo ascertain if the addition of antibiotics to intravenous steroids modifies short and long-term clinical outcomes.

methodsOur study included IBD patients hospitalised between 2009 and 2014 who received intravenous (IV) steroids with or without adjuvant antibiotics. Outcomes of interest included length of stay (LOS), need for medical and surgical rescue therapy during the hospitalisation, and at 90 and 365 days. A meta-analysis of previously published randomised trials was additionally performed.

resultsA total of 354 patients were included [145 ulcerative colitis (UC); 209 Crohn's disease (CD)]. In CD, combination of IV steroids and antibiotics did not change need for in-hospital medical rescue therapy, surgery or hospitalisations at 1 year but was associated with greater LOS (6.1 vs. 4.6 days, P = 0.02). In UC, patients receiving antibiotics were less likely to require in-hospital medical rescue therapy [odds ratio (OR): 0.42, 95% confidence interval (CI): 0.19-0.93] but experienced no statistically significant differences in LOS, in-hospital surgery, re-hospitalisations or surgery by 1 year. A meta-analysis of three relevant randomised trials demonstrated no difference in clinical improvement with antibiotics over placebo (OR: 1.08, 95% CI: 0.50-2.32).

conclusionsThe addition of antibiotics to intravenous steroids for treatment of IBD exacerbations was associated with a reduced need for in-hospital medical rescue therapy in ulcerative colitis without significant long-term benefit, and did not affect short- or long-term outcomes in Crohn's disease.

Indexed as

Adrenal Cortex HormonesAdultAnti-Bacterial AgentsCohort StudiesColitis, UlcerativeCrohn DiseaseDrug Therapy, CombinationFemaleHospitalizationHumansMaleMeta-Analysis as TopicRandomized Controlled Trials as TopicRetrospective StudiesAdrenal Cortex HormonesAnti-Bacterial Agents

Identifiers

PMID26541937
PMCPMC4673010
OpenAlexW2148196830

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.